$1.7 Million NIH Grant to Fund Pain Therapeutics’ Study of PTI-125 as Candidate for Alzheimer’s Treatment

$1.7 Million NIH Grant to Fund Pain Therapeutics’ Study of PTI-125 as Candidate for Alzheimer’s Treatment
The National Institutes of Health (NIH) has awarded Pain Therapeutics a $1.7 million research grant to study PTI-125 as a potential treatment for Alzheimer’s disease. PTI-125 is an oral, small molecule drug developed by the Austin, Texas-based company in collaboration with other partners. It has been shown to significantly improve Alzheimer's neurodegeneration in animal models of the disease and in post mortem brain tissue from Alzheimer's patients, including receptor dysfunction, neuroinflammation, tau protein modification and insulin resistance, as well as plaques and tangles that are hallmarks of the disease. PTI-125 works by binding to a particular site on filamin A (FLNA), a protein critical to beta amyloid’s toxicity. Beta amyloid1-42 (A42) exerts its toxic effects, causing the tangles and plaques found in the brains of people with Alzheimer's. A42's toxic signaling requires the help of FLNA. The effect of PTI-125 on this process was the focus of the study, “PTI-125 reduces amyloid-related Alzheimer's pathogenesis by targeting filamin A,” that appeared in Alzheimer's & DementiaIn this article, researchers demonstrated that PTI-125 prevented amyloid-related Alzheimer’s damage. PTI-125 also had a powerful anti-inflammatory effect in animal models. The NIH grant will allow Pain Therapeutics to begin evaluating PTI-125 in humans. The agency's National Institute on Aging
Subscribe or to access all post and page content.